How Goserelin Acetate Works, Its Uses, and Side Effects

Goserelin acetate is a synthetic hormone drug that works by temporarily shutting down the body’s production of sex hormones, specifically testosterone in men and estrogen in women. Sold under the brand name Zoladex, it belongs to a class of medications called GnRH (gonadotropin-releasing hormone) agonists. Its uses span a surprisingly wide range of conditions, from prostate and breast cancer to endometriosis, uterine fibroids, fertility preservation during chemotherapy, and even early puberty in children.

How Goserelin Works

Your pituitary gland, a pea-sized structure at the base of the brain, normally receives pulses of GnRH from the hypothalamus. Those pulses tell the pituitary to release hormones that in turn signal the ovaries or testes to produce sex hormones. Goserelin mimics GnRH but floods the pituitary receptors with a constant signal rather than the natural pulsing pattern. After a brief initial burst of hormone activity, the pituitary essentially gives up responding and stops sending those signals downstream. The result is a dramatic drop in circulating testosterone or estrogen, depending on the patient’s biology.

This mechanism of desensitizing the pituitary receptors is what makes the drug effective but also what makes it unusual from a pharmaceutical standpoint. Unlike drugs that simply block a receptor, goserelin first overstimulates it before wearing it out. That two-phase action has implications both for how the drug is used clinically and for its side-effect profile.

The Flare Problem in the First Few Weeks

Because goserelin initially stimulates the pituitary before suppressing it, there is a temporary surge in sex hormone levels during the first one to three weeks of treatment. In men with prostate cancer, this testosterone spike can cause what clinicians call “flare,” a worsening of symptoms that can include increased bone pain, urinary obstruction, or even spinal cord compression in patients with advanced disease.¹ The original pharmacological review of goserelin noted this clearly: the early elevation in testosterone can result in disease flare, and the sex-steroid suppression that follows with continued treatment then brings on hot flushes and loss of libido in most patients.²

For patients with advanced prostate cancer, flare is not just uncomfortable; it can be dangerous. The standard approach is to prescribe an antiandrogen drug, such as bicalutamide or flutamide, starting about a week before the first goserelin injection and continuing through the flare window. Evidence suggests that patients without widespread disease but with very high PSA levels should also be considered for flare blockade.³ For patients with localized disease and modest PSA, the risk of a clinically meaningful flare is low enough that many oncologists skip the antiandrogen cover.

Prostate Cancer

Suppressing testosterone to very low levels, sometimes called medical castration, has been a cornerstone of advanced prostate cancer treatment for decades. Goserelin reliably achieves this. In a comparative study of different formulations, all patients treated with goserelin acetate reached castration-level testosterone.⁴ A head-to-head trial comparing goserelin with leuprolide, the other widely used GnRH agonist, found equivalent suppression regardless of whether monthly or three-monthly formulations were used. Mean maximum testosterone levels across the four treatment arms ranged from 0.19 to 0.22 ng/mL, with no statistically significant difference between them.⁵

Goserelin is used across the spectrum of prostate cancer management: as a standalone treatment for advanced metastatic disease, as an adjunct alongside radiation therapy for locally advanced cases, and sometimes as neoadjuvant treatment before surgery. The choice between goserelin and leuprolide often comes down to local availability, cost, and clinician preference rather than meaningful differences in how well they suppress testosterone.

Breast Cancer

In premenopausal women with hormone-receptor-positive breast cancer, shutting down ovarian estrogen production can starve tumor cells of the signal they need to grow. Goserelin is one of the primary tools for achieving this ovarian function suppression. A systematic review of randomized trials found that in the ABCSG Trial 5, which included over a thousand premenopausal women, there was no difference in five-year overall survival between goserelin plus tamoxifen and chemotherapy. However, the five-year recurrence-free survival was significantly better with goserelin plus tamoxifen than with chemotherapy alone, at roughly 83% versus 79%.⁶

That finding was influential because it showed that for certain premenopausal women, hormonal suppression with goserelin could substitute for chemotherapy rather than merely supplement it. Current treatment guidelines have since become more nuanced, with the decision between chemotherapy and ovarian suppression depending on tumor grade, node status, and genomic assays. But the role of goserelin as a core part of endocrine therapy in premenopausal breast cancer remains well established.

Protecting Fertility During Chemotherapy

One of the more hopeful uses of goserelin is protecting ovarian function in young women who need chemotherapy. The idea is that by putting the ovaries into a chemically dormant state during treatment, fewer eggs are destroyed by cytotoxic drugs. A landmark trial published in the New England Journal of Medicine found that ovarian failure occurred in about 22% of breast cancer patients who received chemotherapy alone, compared with roughly 8% of those who also received goserelin. That difference was statistically significant.⁷

A prospective cohort study from China provided further detail, tracking markers of ovarian reserve after chemotherapy. The rate of AMH recovery, a blood marker that reflects the remaining egg supply, was significantly higher in the goserelin group than in the control group, at about 47% versus 22%. Similar patterns were seen for other markers of ovarian function.⁸ Goserelin does not guarantee preserved fertility, but it meaningfully improves the odds for women facing chemotherapy during their reproductive years.

Endometriosis and Uterine Fibroids

Endometriosis, a condition in which tissue similar to the uterine lining grows outside the uterus and causes chronic pain, is driven by estrogen. Goserelin suppresses estrogen and effectively starves those misplaced implants. In a randomized comparison with danazol, an older drug with more androgenic side effects, goserelin reduced endometriosis scores by about 53% after 24 weeks of treatment, compared with 33% for danazol. Endometrial implants specifically shrank by 56% with goserelin versus 46% with danazol.⁹ A separate trial found that total pelvic symptom scores dropped by over 90% by the end of goserelin treatment, and about a third of patients who underwent follow-up laparoscopy had complete resolution of visible endometrial deposits.¹⁰

For uterine fibroids, goserelin serves a somewhat different purpose. Fibroids are benign uterine growths that can cause heavy menstrual bleeding, often leading to iron-deficiency anemia. Goserelin shrinks fibroids and stops menstrual bleeding, giving the body time to rebuild iron stores before surgery. In a phase III trial, women who received the 10.8 mg goserelin depot before surgery had significantly higher hemoglobin levels at 12 weeks compared with a control group, and were about six times more likely to achieve an increase in hemoglobin of at least 2 g/dL.¹¹ A more recent multicenter study in Chinese patients confirmed significant fibroid shrinkage and hemoglobin recovery after 12 weeks of treatment.¹²

Goserelin is not a permanent treatment for either condition. In endometriosis, symptoms often return after the drug is stopped. In fibroids, the growths tend to regain size once estrogen returns. The drug is typically used as a bridge to surgery, or for short-term symptom control when surgery is delayed or inappropriate.

Precocious Puberty in Children

When puberty begins abnormally early, GnRH agonists like goserelin can press pause on the process. The goal is to delay development until a more typical age, preserving adult height potential and sparing children the social and psychological stress of early physical maturation. A study comparing goserelin and leuprolide in children with central precocious puberty found that both drugs achieved similar biochemical suppression of puberty during the first 12 months of treatment.¹³

An interesting observation after treatment stops is that menstruation tends to resume somewhat slowly. One study found a relatively long interval of about a year and a half between stopping goserelin and the onset of menarche, which researchers speculated might reflect lingering suppression of the hormonal axis by the long-acting formulation.¹⁴ Leuprolide is used more commonly than goserelin for this indication in many countries, but goserelin remains a valid alternative where it is available.

How It Is Given

Goserelin comes as a small solid implant, roughly the size of a grain of rice, preloaded in a syringe. It is injected under the skin of the abdominal wall, typically below the navel.¹⁵ Two depot sizes are available: a 3.6 mg implant that lasts about a month and a 10.8 mg implant that lasts about three months. Once injected, the implant slowly biodegrades and releases a steady supply of the drug. The injection itself uses a larger gauge needle than a typical shot, and many patients describe it as uncomfortable but tolerable. Some clinicians have explored alternative injection sites, particularly for breast cancer patients who may have had abdominal surgery or find the standard site problematic.

Research into next-generation delivery systems is ongoing. One experimental formulation encapsulated goserelin in a combination of a hydrogel and biodegradable polymer microspheres, achieving very low initial burst release and a prolonged release window of about 49 days, along with a dramatically higher bioavailability compared with the standard Zoladex implant.¹⁶ Formulations like these could eventually extend the dosing interval even further, reducing the number of clinic visits patients need.

Bone Loss and How to Manage It

Because sex hormones play a major role in maintaining bone density, suppressing them with goserelin predictably weakens bones. In premenopausal women with breast cancer, a randomized trial found that two years of goserelin alone caused an average bone mineral density loss of about 5%. When goserelin was combined with tamoxifen, the loss was smaller, around 1.4%. Encouragingly, the goserelin-alone group showed partial recovery of bone density one year after stopping treatment.¹⁷

For women receiving goserelin for gynecological conditions like endometriosis, the standard approach is “add-back” therapy: small doses of hormones or other bone-protective agents given alongside goserelin to mitigate bone loss without undermining the drug’s therapeutic effect. Bisphosphonates have shown promise for preserving bone density in this context.¹⁸ Not all add-back regimens are equally effective, though. One study found that medrogestone, a progestogen, did not prevent lumbar spine bone loss in premenopausal women receiving goserelin, with about a 4% loss at six months regardless of whether the add-back was given.¹⁹ The choice of add-back agent matters, and patients on prolonged courses should have their bone density monitored.

Metabolic and Cardiovascular Side Effects in Men

In men with prostate cancer, androgen deprivation therapy with goserelin affects more than just the prostate. Reduced testosterone leads to changes in body composition, including increased fat mass and decreased lean muscle. Insulin resistance, elevated cholesterol, and a higher risk of metabolic syndrome have all been reported as consequences of the low-testosterone state. These metabolic changes appear within months of starting treatment and can persist even after the drug is stopped.²⁰

These risks are not unique to goserelin; they apply to any form of androgen deprivation. But because goserelin is often used for extended periods in prostate cancer, the cumulative cardiovascular and metabolic burden can be substantial. Current guidelines recommend that men starting androgen deprivation therapy be screened for diabetes risk and cardiovascular disease, and that modifiable risk factors like weight, blood sugar, and cholesterol be actively managed throughout treatment.

Testosterone Recovery After Stopping Treatment

A question many prostate cancer patients have is whether their testosterone will return to normal after goserelin is discontinued. The answer depends heavily on age and treatment duration. In one study, about 79% of men eventually recovered normal testosterone levels, with a median recovery time of 10 months. Advanced age and lower pre-treatment testosterone were associated with slower recovery. Interestingly, men who had used three-month depot formulations took longer to recover than those on monthly injections.²¹

A separate study painted a more sobering picture in men treated for longer periods. After a mean follow-up of about 31 months of therapy, over half still had castrate-level testosterone at the time treatment was stopped, and only one patient had reached a normal level at that assessment. Among those who started therapy after age 70, roughly four out of five remained castrated.²² The takeaway is that recovery is likely for younger men on shorter courses, but older men who have been on goserelin for years should not assume their testosterone will bounce back.

How Goserelin Compares With GnRH Antagonists

GnRH antagonists like degarelix represent a newer approach. Instead of first stimulating and then exhausting the pituitary, antagonists block the GnRH receptor immediately. The practical advantage is speed: testosterone levels fall within days rather than weeks, and there is no flare. A systematic review and meta-analysis comparing degarelix with GnRH agonists found that degarelix achieved faster testosterone reduction in the first 28 days. After that initial window, testosterone suppression and prostate volume reduction were not significantly different between the two approaches.²³ A clinical review similarly concluded that while degarelix produced a more rapid initial decline in testosterone and PSA, the long-term suppression was comparable to goserelin.²⁴

The tradeoff for degarelix is at the injection site. The meta-analysis found that injection-site reactions were dramatically more common with degarelix than with GnRH agonists. Degarelix also requires monthly injections, whereas goserelin offers a three-month depot option that many patients prefer for convenience. For patients with advanced disease where flare poses a genuine risk and an antiandrogen co-prescription is undesirable, degarelix has a clear advantage in those first weeks. For patients on long-term maintenance, goserelin’s depot options and established track record keep it competitive.

Cost Considerations

The economics of goserelin vary dramatically by country and healthcare system. An older Norwegian cost analysis compared goserelin with surgical castration (orchiectomy) for metastatic prostate cancer and found that surgical removal of the testes was less expensive over a three-year period, with costs crossing over at about 25 months. The study concluded that orchiectomy was the more cost-effective choice when life expectancy exceeded two years.²⁵ That said, many men strongly prefer a reversible injection to irreversible surgery for psychological reasons, and quality-of-life scores in that study were not dramatically different between the two groups.

A more recent cost-effectiveness analysis from Iran compared goserelin with triptorelin and leuprolide over a 20-year horizon. Goserelin came out as the most cost-effective option, with the lowest total cost and a quality-adjusted life-year estimate that, while slightly lower than the other two drugs, was favorable when weighed against the price difference.²⁶ These analyses are highly sensitive to local drug pricing, and the availability of generic formulations is gradually shifting the landscape. The challenge of producing generics for GnRH agonists is nontrivial, because goserelin’s mechanism of desensitizing pituitary receptors makes bioequivalence harder to demonstrate than for simpler drugs.²⁷

Origins as a Synthetic Peptide Drug

Goserelin was approved by the FDA in 1989 and belongs to a class of molecules called azapeptides, which are modified versions of natural peptide chains engineered for greater stability and potency. It was among the first azapeptide-based drugs to reach clinical use and remains one of the best-known examples of this chemical class. The development of goserelin represented a significant step in demonstrating that synthetic peptides could be turned into practical, long-acting medications. The other famous azapeptide drug, the HIV medication atazanavir, did not arrive until 2003, underscoring how early goserelin was in this space. More than three decades after its approval, the drug is still widely prescribed worldwide, a testament to both its versatility and the robustness of its depot delivery system.